Metabolic Syndrome in Breast Cancer Patients: An Observational Study. (October 2021)

• Record Type: Journal Article
• Authors: Khare, Siddhant; Irrinki, Santhosh; Sakaray, Yashwant Raj; Bal, Amanjit; Singh, Tulika; Singh, Gurpreet
• Is Part Of: Breast cancer. Volume 15(2021)
• Publication Date: 2021-10
• Subjects: Breast cancer -- metabolic syndrome -- risk factors -- clinicopathological parameters; Breast -- Cancer -- Periodicals; 616.99449
• DOI: 10.1177/11782234211026788
• Languages: English
• ISSNs: 1178-2234

Abstract

Background: The reported association between metabolic syndrome (MetS) and breast cancer may have a significant impact on the incidence and mortality related to breast cancer. We undertook this study to find if the disease is different in patients with MetS. Materials and Methods: Patients with biopsy-proven breast cancer were divided into groups based on the presence or absence of MetS (according to the IDF definition of 2006) and also based on menopausal status. The presence of known risk and prognostic factors were also recorded, and the groups were compared. Results: A total of 305 patients were recruited, of which 191 (62.6%) had MetS. Patients with MetS were older than those without (52.1 versus 48.3 years, P = .014) and had a lower incidence of nulliparity (4.1% vs 12.8%, P = .005) and dense breasts (2.9% in MetS vs 10.8% in no MetS, P = .009). On further dividing into premenopausal and postmenopausal, these differences persisted only in premenopausal patients. MetS group had a lower number of HER2-positive tumours (14.3% for MetS, 23.9% for no MetS; P = .036). After dividing into premenopausal and postmenopausal, significant differences were observed in distant metastases (5.4% in MetS vs 16.1% in no MetS, P = .045) and in grade (higher grade in MetS, P = .05) in premenopausal patients. In postmenopausal patients, difference was observed in HER2 positivity (12.3% in MetS vs 28.8% in no MetS, P = .008). Conclusions: Breast cancer in patients with MetS may not be significantly different from breast cancer in patients without MetS.